NASDAQ:MESO Mesoblast (MESO) Stock Price, News & Analysis $6.10 -0.31 (-4.84%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$6.03▼$6.4950-Day Range$5.84▼$8.2752-Week Range$1.61▼$8.66Volume81,458 shsAverage Volume936,828 shsMarket Capitalization$696.49 millionP/E RatioN/ADividend YieldN/APrice Target$22.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Mesoblast alerts: Email Address Mesoblast MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside268.9% Upside$22.50 Price TargetShort InterestBearish0.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.09Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.74) to ($0.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 starsMedical Sector510th out of 910 stocksBiological Products, Except Diagnostic Industry80th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingMesoblast has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMesoblast has only been the subject of 3 research reports in the past 90 days.Read more about Mesoblast's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.67% of the outstanding shares of Mesoblast have been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Mesoblast has recently increased by 15.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MESO. Previous Next 2.3 News and Social Media Coverage News SentimentMesoblast has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Mesoblast this week, compared to 3 articles on an average week.Search Interest6 people have searched for MESO on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.43% of the stock of Mesoblast is held by institutions.Read more about Mesoblast's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Mesoblast are expected to grow in the coming year, from ($0.74) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Mesoblast Stock (NASDAQ:MESO)Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More MESO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MESO Stock News HeadlinesSeptember 5 at 3:47 AM | americanbankingnews.comMesoblast (NASDAQ:MESO) Rating Lowered to Sell at StockNews.comSeptember 4 at 1:08 AM | msn.comMesoblast Limited (NASDAQ:MESO) Q4 2024 Earnings Call TranscriptSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 3, 2024 | msn.comIs Mesoblast (MESO) The Best Australian Stock To Buy According to Hedge Funds?August 31, 2024 | americanbankingnews.comMesoblast (NASDAQ:MESO) Rating Reiterated by Cantor FitzgeraldAugust 30, 2024 | markets.businessinsider.comMesoblast (MESO) Receives a Buy from Piper SandlerAugust 29, 2024 | seekingalpha.comMesoblast Limited (MESO) Q4 2024 Earnings Call TranscriptAugust 29, 2024 | msn.comMesoblast share price slumps as FY24 earnings fail to impressSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 29, 2024 | americanbankingnews.comMesoblast (NASDAQ:MESO) Raised to Buy at Jefferies Financial GroupAugust 28, 2024 | seekingalpha.comMesoblast Limited 2024 Q4 - Results - Earnings Call PresentationAugust 28, 2024 | globenewswire.comMesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024August 28, 2024 | americanbankingnews.comMesoblast (NASDAQ:MESO) Upgraded to "Hold" by StockNews.comAugust 27, 2024 | msn.comMesoblast FY Earnings PreviewAugust 27, 2024 | globenewswire.comMesoblast Financial Results and Corporate Update WebcastAugust 22, 2024 | msn.com2 ASX healthcare shares outperforming peers on positive company newsAugust 18, 2024 | finance.yahoo.comMESO Sep 2024 6.000 put (MESO240920P00006000)August 14, 2024 | msn.comDown 53% in a year! What went wrong for BrainChip shares?See More Headlines Receive MESO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/30/2023Today9/07/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CUSIPN/A CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036Fax61-3-9639-6030Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$22.50 High Stock Price Target$34.00 Low Stock Price Target$11.00 Potential Upside/Downside+268.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.21 Current Ratio2.71 Quick RatioN/A Sales & Book Value Annual Sales$5.90 million Price / Sales118.01 Cash FlowN/A Price / Cash FlowN/A Book Value$6.16 per share Price / Book0.99Miscellaneous Outstanding Shares114,178,000Free Float92,713,000Market Cap$696.49 million OptionableOptionable Beta3.48 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Silviu Itescu FACP (Age 67)FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Comp: $738.74kDr. Eric A. Rose M.D. (Age 73)Chief Medical Officer & Executive Director Comp: $625.46kMr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerMr. Peter T. Howard B.Sc. (Age 56)L.L.B., LLB (Hons), General Counsel & Corporate Executive Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersMr. Michael Schuster BSc (Age 47)M.B.A., MS, Head of Pharma Partnering Ms. Geraldine Storton B.Sc.M.B.A., MMS, Head of Regulatory Affairs & Quality ManagementMr. Justin Horst B.S.Head of ManufacturingMs. Niva Sivakumar B.Com.L.L.B., Joint Company SecretaryMr. Paul Hughes BPHARMJoint Company SecretaryMore ExecutivesKey CompetitorsHUTCHMEDNASDAQ:HCMIovance BiotherapeuticsNASDAQ:IOVAXenon PharmaceuticalsNASDAQ:XENESpringWorks TherapeuticsNASDAQ:SWTXMerusNASDAQ:MRUSView All CompetitorsInstitutional OwnershipMarshall Wace LLPBought 82,576 shares on 8/14/2024Ownership: 0.072%XTX Topco LtdBought 15,063 shares on 8/12/2024Ownership: 0.013%Rathbones Group PLCBought 14,017 shares on 8/9/2024Ownership: 0.012%Pine Valley Investments Ltd Liability CoBought 11,714 shares on 7/30/2024Ownership: 0.010%Chapin Davis Inc.Bought 5,000 shares on 7/19/2024Ownership: 0.013%View All Institutional Transactions MESO Stock Analysis - Frequently Asked Questions How have MESO shares performed this year? Mesoblast's stock was trading at $2.20 at the beginning of 2024. Since then, MESO stock has increased by 177.3% and is now trading at $6.10. View the best growth stocks for 2024 here. How were Mesoblast's earnings last quarter? Mesoblast Limited (NASDAQ:MESO) issued its quarterly earnings results on Wednesday, August, 30th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06. The company had revenue of $2.14 million for the quarter, compared to the consensus estimate of $2 million. When did Mesoblast's stock split? Shares of Mesoblast reverse split on the morning of Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. When did Mesoblast IPO? Mesoblast (MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. Who are Mesoblast's major shareholders? Mesoblast's top institutional shareholders include Marshall Wace LLP (0.07%), XTX Topco Ltd (0.01%), Chapin Davis Inc. (0.01%) and Rathbones Group PLC (0.01%). How do I buy shares of Mesoblast? Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP) and Novavax (NVAX). This page (NASDAQ:MESO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.